PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio • Pipeline portfolio: Global diabetes drugs market • Pipeline portfolio: Global hyperphosphatemia drugs market • Pipeline portfolio: Global anti-obesity drugs market PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by type of disease • Diabetes • Obesity • Hypercholesterolemia • Lysosomal storage diseases PART 08: Global diabetes drugs market • Market overview • Global type 1 diabetes market • Global type 2 diabetes drugs market • Vendors in global diabetes drugs market PART 09: Global hypercholesterolemia drugs market • Market overview • Vendors in global hypercholesterolemia drugs market PART 10: Global lysosomal storage diseases market • Market overview • Vendors in global lysosomal storage disorders drugs market PART 11: Global anti-obesity drugs market • Market overview • Vendors in global anti-obesity drugs market PART 12: Geographical segmentation • Global metabolic disorders therapeutics market by geography 2015-2020 • Metabolic disorders therapeutics market in Americas • Metabolic disorders therapeutics market in EMEA • Metabolic disorders therapeutics market in APAC PART 13: Market drivers • Patient assistance programs • Special regulatory designations for rare diseases • Increase in academia-industry collaborations for drug development PART 14: Impact of drivers PART 15: Market challenges • Low compliance and adherence rates • High cost of therapies • Complex storage conditions and distribution policies for insulin PART 16: Impact of drivers and challenges PART 17: Market trends • Focus on oral insulin therapies • Strong and diversified pipeline portfolio • Strategic collaborations and acquisitions PART 18: Vendor landscape • Competitive scenario • Other prominent vendors • PART 19: Key vendor analysis • Novo Nordisk • Sanof • Merck • AstraZeneca • Eli Lilly PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015 Exhibit 03: Impact of key customer segments on market 2015 Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015 Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions) Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis Exhibit 08: Five forces analysis Exhibit 09: Global metabolic disorders therapeutics market by type of disease Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020) Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions) Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015 Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions) Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions) Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions) Exhibit 17: Market share analysis of vendors in global diabetes drugs market Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions) Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions) Exhibit 20: Market dynamics of hypercholesterolemia drugs Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015 Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions) Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015 Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions) Exhibit 26: Key events in treatment of lysosomal storage diseases Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions) Exhibit 29: Products offered by major vendors in global anti-obesity drugs market Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020 Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020 Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions) Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015 Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015 Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015 Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions) Exhibit 37: Prevalence of obesity in various countries in Europe 2025 Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions) Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025 Exhibit 41: Few metabolic disorder drugs with patient assistance programs Exhibit 42: Impact of drivers Exhibit 43: Impact of drivers and challenges Exhibit 44: Oral insulin pipeline portfolio Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms Exhibit 46: Key vendors ranking 2015 Exhibit 47: Geographical presence of key vendors Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020 Exhibit 49: Novo Nordisk: Profile Exhibit 50: Novo Nordisk: Strength analysis Exhibit 51: Novo Nordisk: Growth strategy matrix Exhibit 52: Novo Nordisk: Growth opportunity assessment Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015 Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions) Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions) Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions) Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions) Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions) Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions) Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions) Exhibit 62: Sanofi: Business segmentation by revenue 2015 Exhibit 63: Sanofi: Profile Exhibit 64: Sanofi: Strength analysis Exhibit 65: Sanofi growth strategy matrix Exhibit 66: Sanofi: Growth opportunity assessment Exhibit 67: Key product offerings in diabetes market ($ billions) Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions) Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions) Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions) Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions) Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions) Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015 Exhibit 74: Merck: Strength profile Exhibit 75: Merck: Strength analysis Exhibit 76: Merck: Growth strategy matrix Exhibit 77: Merck: Opportunity assessment Exhibit 78: Top selling diabetes drugs in 2015 Exhibit 79: Merck: Diabetes segmentation by revenue 2015 Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions) Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions) Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions) Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions) Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions) Exhibit 85: AstraZeneca: Profile Exhibit 86: AstraZeneca: Strength analysis Exhibit 87: AstraZeneca: Growth strategy matrix Exhibit 88: AstraZeneca: Opportunity assessment Exhibit 89: Top selling diabetes drugs in 2015 ($ billions) Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions) Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions) Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions) Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions) Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions) Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue Exhibit 96: Eli Lilly: Profile Exhibit 97: Eli Lilly: Strength analysis Exhibit 98: Eli Lilly growth strategy matrix Exhibit 99: Eli Lilly: Opportunity assessment Exhibit 100: Top selling diabetic drugs 2015 ($ billions) Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions) Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions) Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions) Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)

Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lilly. Other Prominent Vendors in the market are: AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical Company, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Santaris Pharma, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies , Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.